Pulmonary Embolism
📧 Sign up to get email alerts when something new happens for Pulmonary Embolism.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-06-18FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for ENOXAPARIN SODIUM by Sandoz Inc, signaling an approved change to the product's status under the …
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events [NA]
A completed clinical trial evaluating non-contrast 4DCT imaging for detecting pulmonary thromboembolic events with posted results.
-
FDA approval · 2020-05-06FDA Approved: DABIGATRAN ETEXILATE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the original application for a generic dabigatran etexilate (ANDA 207961) from XLCare Pharmaceuticals, confirming the generic’s…
-
FDA approval · 2020-04-02FDA Approved: HEPARIN SODIUM — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' original application for a generic heparin sodium product.
-
FDA approval · 2020-03-20FDA Approved: PULMOTECH MAA — Original Application (Curium US LLC)
FDA approves Pulmotech MAA, a kit for preparing Technetium-99m-labeled aggregated albumin used for pulmonary perfusion imaging.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-03-19FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Italfarmaco SpA)
FDA approved a supplemental application for ENOXAPARIN SODIUM submitted by Italfarmaco SpA.
-
FDA approval · 2020-03-11FDA Approved: DABIGATRAN ETEXILATE — Original Application (Major Pharmaceuticals)
FDA approved the original application for dabigatran etexilate from Major Pharmaceuticals, approving a generic version of the anticoagulant …
-
CLINICAL_TRIALS withdrawal · 2020-02-17Clinical Trial Update: Use of Gadolinium in CT Pulmonary Angiography [Phase 4]
A Phase 4 clinical trial investigating gadolinium use in CT pulmonary angiography has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. [Phase 4]
A Phase 4 clinical trial evaluating low molecular weight heparin followed by dabigatran for acute intermediate-risk pulmonary embolism was t…
-
CLINICAL_TRIALS trial_result · 2020-01-06Clinical Trial Update: Education Bundle to Decrease Patient Refusal of VTE Prophylaxis [NA]
A completed clinical trial evaluating an education bundle to reduce patient refusal of venous thromboembolism prophylaxis.
-
FDA approval · 2019-11-20FDA Approved: HEPARIN SODIUM — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for Heparin Sodium from Gland Pharma Limited (ANDA205323). This action confirms continued availabili…
-
CLINICAL_TRIALS trial_result · 2019-11-07Clinical Trial Update: Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation [Phase 4]
Phase 4 clinical trial update examining vascular calcification and stiffness associated with oral anticoagulation in patients with permanent…
-
FDA approval · 2019-10-31FDA Approved: WARFARIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Warfarin Sodium (Warfarin) from Amneal Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA) [Phase 2]
Phase 2 clinical trial update for a recombinant tissue-type plasminogen activator derivative (rPA) in acute pulmonary embolism.
-
FDA approval · 2019-09-26FDA Approved: WARFARIN SODIUM — Supplemental Application (Exelan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Warfarin Sodium by Exelan Pharmaceuticals. This action updates the regulatory status of this…
-
FDA approval · 2019-09-20FDA Approved: JANTOVEN — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for JANTOVEN (warfarin sodium) submitted by Upsher-Smith Laboratories, LLC.
-
FDA approval · 2019-08-23FDA Approved: XARELTO — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for XARELTO (rivaroxaban) filed by Janssen Pharmaceuticals, resulting in labeling changes to the pro…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy [Phase 3]
Phase 3 trial update on ultrasound accelerated thrombolysis for submassive and massive pulmonary embolism has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin [EARLY_Phase 1]
A Phase Early 1 trial evaluating anti-Xa level monitoring in surgery patients on fixed-dose heparin has completed with results posted.
-
FDA approval · 2019-05-28FDA Approved: HEPARIN SODIUM — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals Inc.'s Heparin Sodium as an Original Application (ANDA 211007), making a generic injectable anticoagul…
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism [Phase 3]
A Phase 3 trial evaluating dabigatran etexilate as the primary treatment for malignancy-associated venous thromboembolism is underway, with …
-
FDA approval · 2019-03-14FDA Approved: ENOXAPARIN SODIUM — Original Application (Amphastar Pharmaceuticals, Inc.)
FDA approved Amphastar Pharmaceuticals' generic enoxaparin sodium injection (ANDA 208600). This marks approval of a generic version of enoxa…
-
CLINICAL_TRIALS trial_result · 2019-02-08Clinical Trial Update: Diagnosis of Pulmonary Embolism by Doppler Signals [NA]
A clinical trial evaluating Doppler signal-based diagnosis of pulmonary embolism was terminated.
-
FDA approval · 2018-12-20FDA Approved: HEPARIN SODIUM AND DEXTROSE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Hospira's Heparin Sodium and Dextrose (heparin sodium) product, authorizing changes under the ND…
-
FDA approval · 2018-12-14FDA Approved: HEPARIN SODIUM — Original Application (NorthStar RxLLC)
The FDA approved NorthStar RxLLC's original application for generic heparin sodium (ANDA211005).